Skip to main content

GM9 Glucose Analyser

The Analox GM9 analyser is an ultra-fast stand alone system for glucose analysis in plasma and other fluids. The system offerss exceptional precision and accuracy. 

Application Areas

Diabetes monitoring - glucose analysis

Clamp studies


After calibration with a standard of the selected metabolite, the single injection of sample is all that is needed to obtain a result and prepare the analyser for the next analysis. Sample injection via an accurate positive displacement pipette triggers the complete analytical cycle and a hard-copy result is printed within 25 seconds.

Order Number





Instrument Specification

Method Enzymatic oxygen-rate
Sensor Clark-type amperometric oxygen electrode
Reaction Temp. 30°C
Display 32 character backlit LCD
Printer 16 column dot matrix, 1 line/sec.
Statistics Sequential, giving mean, S.D and C.V.
Interface Serial data port
Power 100-250VAC, 50-60Hz, 12-15VDC, 60VA
Dimensions 23cm(width) x 29cm(depth) x 15cm(height)
Weight 3.8Kg (Portable, 6Kg)


Example data below, please see GM9 Brochure or Analyte Technical Bulletins for full specifications

Analytical Perfomance

  Precision Accuracy (Method Comparisons) Linearity
Glucose C.V. of 1.0% @ 5 mmol/L (plasma) C.V. 1.4 % @ 10 mmol/L (plasma) i) Method comparison vs Hexokinase: y(Analox) = 0.985x - 0.14 mmol/L, r = 0.999, n = 156 ii) Method comparison vs Beckman; y(Analox) = 1.005x - 0.07 mmol/L, r = 0.999, n = 123 30.0 mmol/L (540 mg/dl) for 10µl samples; 50.0 mmol/L (900 mg/dl) for 5µl samples

Ordering Information


For a full list of ordering info please visit the support page.

GMRD-002A Glucose oxidase reagent, 250ml, 360 cycles
GMRD-009 Glucose standard, 2.5mmol/L, 30ml
GMRD-010 Glucose standard, 5.0mmol/L, 30ml
GMRD-011 Glucose standard, 8.0mmol/L, 30ml
GMRD-012 Glucose standard, 25.0mmol/L, 30ml
GMRD-055 Closures for capillaries, per 100
GMRD-056 Closures for capillaries, per 500

Newsletter Sign Up

If you would like to be kept informed of the work and news of Analox, please subscribe to our newsletter.